Identification of Metabolite Biomarkers of the Designer Hallucinogen 25I-NBOMe in Mouse Hepatic Microsomal Preparations and Human Urine Samples Associated with Clinical Intoxication.

@article{Poklis2015IdentificationOM,
  title={Identification of Metabolite Biomarkers of the Designer Hallucinogen 25I-NBOMe in Mouse Hepatic Microsomal Preparations and Human Urine Samples Associated with Clinical Intoxication.},
  author={Justin L Poklis and Sara K. Dempsey and Kai Liu and Joseph K. Ritter and Carl E. Wolf and Shijun Zhang and Alphonse Poklis},
  journal={Journal of analytical toxicology},
  year={2015},
  volume={39 8},
  pages={
          607-16
        }
}
'NBOMe' (dimethoxyphenyl-N-[(2-methoxyphenyl)methyl]ethanamine) derivatives are a new class of designer hallucinogenic drugs widely available on the Internet. Currently, 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) is the most popular abused derivative in the USA. There are little published data on the absorption, metabolism and elimination of 25I-NBOMe, or any of the other NBOMe derivatives. Therefore, there are no definitive metabolite biomarkers. We… CONTINUE READING
2
Twitter Mentions